Novo Nordisk (NVO) rated Buy as oral Wegovy lifts GLP-1 sales, expands obesity market and boosts 2026 guidance.

S&P 500 earnings surged 60% in 3 years—dot-com bust fears? See why cash flows, capex discipline, and stricter accounting may ...

Allogene Therapeutics offers upside potential driven by the pivotal ALPHA3 trial for Cema-cel in first-line large B-cell ...

Build a resilient portfolio with a simple 4-point blueprint: diversify across 42+ positions, reinvest 25% cashflows, and win ...

Enterprise Products Partners offers a compelling 6% yield and trades at an attractive 10.3x price-to-cash flow. Read why EPD ...

Vince Holding Corp. is executing a turnaround, focusing on premium apparel, e-commerce, and operational efficiency. Learn why ...

DoubleLine Yield Opportunities Fund offers a diversified, high-yield fixed income portfolio with a 9.93% dividend yield.

Intel faces asymmetric downside risk as AI infrastructure efficiency may outpace monetized demand, risking valuation ...

Grayscale CoinDesk Crypto 5 ETF has transitioned to an ETF structure but remains uncompetitive due to its expense ratio. Read ...

Kimberly-Clark's (KMB) organic sales growth but pricing headwinds persist. The macro environment improved somewhat with ...

Track Lumentum’s 33% pullback from AI-fueled highs, the four-wave selloff, and what OCS/CPO and 1.6T optical demand means ...

Novartis already received FDA approval of ITVISMA as a gene therapy for the treatment of patients with SMA. Read why NVS ...